November 1st 2024
Panelists discuss the currently available chimeric antigen receptor T-cell therapies for early relapse multiple myeloma, examining their place within the treatment paradigm and how factors such as product type (cilta-cel vs ide-cel) and high-risk features (such as minimal residual disease positivity post induction and extramedullary disease) influence clinical decision-making.
Panelists discuss the key disease and patient factors considered when choosing between triplet and quadruplet induction regimens for patients with transplant-ineligible multiple myeloma, as well as the unmet needs that persist in the treatment landscape for both transplant-eligible and ineligible populations.
October 25th 2024
Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.
Panelists discuss the importance of minimal residual disease negativity as a primary outcome measure and the treatment strategies for patients who are eligible for transplantation but choose to decline it, including preferred induction regimens for this population.
October 18th 2024
Panelists discuss whether daratumumab quadruplet induction regimens should be considered the new standard of care for newly diagnosed transplant-eligible patients and explore scenarios in which a triplet induction regimen might still be appropriate. They also review the findings from the ISKIA and GMMG-CONCEPT trials, including considerations for using isatuximab-carfilzomib (IsaKRd) over D-VRd.
Panelists discuss the findings of the PERSEUS trial and the recent cytogenetic risk analysis for patients with newly diagnosed transplant-eligible multiple myeloma. They then explore the CASSIOPEIA trial and its implications regarding daratumumab quadruplet induction regimens.
June 17th 2024
Noopur S. Raje, MD, and Yan Leyfman, MD, discuss the phase 3 DREAMM-7 and DREAMM-8 trials on OncLive News Network: On Location.
June 2nd 2024
OncLive® will be LIVE with OncLive® News Network: On Location at the 2024 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference
January 30th 2024
Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.
Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.
January 23rd 2024
Dr. Abonour and Dr. Raje provide an overview of the results that were presented at ASH 2023 of the CIBMTR registry and CARTITUDE-2 trial which was the study of ciltacabtagene autoleucel (cilta-cel) in patients with MM and 1-3 prior lines of therapy (Cohort A) and with early relapse after first line treatment (cohort B).
Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.
January 16th 2024
Noopur Raje, MD discusses the rationale for utilizing BCMA-targeted CAR-T cell therapy in myeloma patients and uncover the similarities and differences when compared to BCMA bispecific.
Rafat Abonour, MD briefly summarizes the current treatment landscape for Relapsed/Refractory Multiple Myeloma (R/R MM) and discusses the diverse strategies and advancements in managing this complex disease.
March 13th 2023
The panel closes their discussion with a look at the remaining unmet needs in multiple myeloma treatment.
The panel takes a look at the possible re-approval of belantamab as a treatment for multiple myeloma in the future.
Sagar Lonial, MD, starts a conversation on infection and hypogamma prevention in patients receiving CAR-T therapy for multiple myeloma.
March 6th 2023
Noopur Raje, MD, muses on how to manage CRS and ICANS in patients being treated for multiple myeloma, and how serious these conditions truly are.
Dr Hana Safah continues the discussion on novel targets in multiple myeloma with a look at FcRH5 and data on cevostamab.
February 27th 2023
Amrita Krishnan, MD, discusses targeting GPRC5D in multiple myeloma, and where it fits in the treatment sequence.